- Home
- FTRK vs ALEC Comparison
FTRK vs ALEC Comparison
Compare FTRK & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTRK
- ALEC
- Stock Information
- Founded
- FTRK 2012
- ALEC 2013
- Country
- FTRK Singapore
- ALEC United States
- Employees
- FTRK N/A
- ALEC N/A
- Industry
- FTRK
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTRK
- ALEC Health Care
- Exchange
- FTRK NYSE
- ALEC Nasdaq
- Market Cap
- FTRK 134.1M
- ALEC 124.0M
- IPO Year
- FTRK 2025
- ALEC 2019
- Fundamental
- Price
- FTRK $0.62
- ALEC $1.76
- Analyst Decision
- FTRK
- ALEC Buy
- Analyst Count
- FTRK 0
- ALEC 7
- Target Price
- FTRK N/A
- ALEC $4.70
- AVG Volume (30 Days)
- FTRK 1.6M
- ALEC 476.6K
- Earning Date
- FTRK 01-01-0001
- ALEC 08-06-2025
- Dividend Yield
- FTRK N/A
- ALEC N/A
- EPS Growth
- FTRK N/A
- ALEC N/A
- EPS
- FTRK N/A
- ALEC N/A
- Revenue
- FTRK $751,195.00
- ALEC $88,339,000.00
- Revenue This Year
- FTRK N/A
- ALEC N/A
- Revenue Next Year
- FTRK N/A
- ALEC $319.82
- P/E Ratio
- FTRK N/A
- ALEC N/A
- Revenue Growth
- FTRK N/A
- ALEC N/A
- 52 Week Low
- FTRK $0.53
- ALEC $0.87
- 52 Week High
- FTRK $9.69
- ALEC $6.67
- Technical
- Relative Strength Index (RSI)
- FTRK N/A
- ALEC 60.62
- Support Level
- FTRK N/A
- ALEC $1.56
- Resistance Level
- FTRK N/A
- ALEC $1.70
- Average True Range (ATR)
- FTRK 0.00
- ALEC 0.11
- MACD
- FTRK 0.00
- ALEC 0.01
- Stochastic Oscillator
- FTRK 0.00
- ALEC 86.11
About FTRK FAST TRACK GROUP
Fast Track Group is a regional entertainment-focused event management and marketing company that provides a full range of services including experiential marketing, artiste endorsement and management, movie premiere organizations, grand openings, and concerts. It also creates, develops, organizes, hosts, and manages various events and concerts.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.